|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. AN-1792,
a prototype active vaccine
The first drug development candidate to be evaluated in clinical
trials under the collaboration with Wyeth, AN-1792 (an
immunoconjugate vaccine), was discontinued in 2002 when a subset
of patients (6%) developed a type of brain inflammation. We
believe the AN-1792 program played a major role in advancing the
understanding of the relationship between beta amyloid and
Alzheimer’s disease, and has contributed to a growing body
of scientific evidence pointing to the promise of immunotherapy
as a potential treatment for Alzheimer’s disease.
Long-term
follow-up
data presented in 2007 evaluated participants from the AN-1792
Phase 2 clinical trial and found that 4.5 years after
dosing had stopped, patients who had responded to treatment by
generating anti-Aß antibodies continued to show
significantly slower decline, compared to placebo patients, on
two key measures of patient function: the Disability Assessment
for Dementia and the Dependence Scale.
|
| |||||||
